DeepMed Research

SCRI Development Innovations, LLC

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma

Phase 1

Terminated

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Carcinoma

Interventions: Drug: Pazopanib
Drug: Doxil

First Posted Date: 2009-12-21

Last Posted Date: 2021-10-28

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 22

Registration Number: NCT01035658

Locations: 🇺🇸
Florida Hospital Cancer Insitute, Orlando, Florida, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States

and more 1 locations

Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Amrubicin

First Posted Date: 2009-12-16

Last Posted Date: 2022-05-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 78

Registration Number: NCT01033032

Locations: 🇺🇸
The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇺🇸
Berks Hematology Oncology Associates, West Reading, Pennsylvania, United States
🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States

and more 13 locations

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Bendamustine
Drug: Bortezomib
Drug: Rituximab

First Posted Date: 2009-12-10

Last Posted Date: 2016-08-19

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 55

Registration Number: NCT01029730

Locations: 🇺🇸
Florida Cancer Specialists, Ft. Myers, Florida, United States
🇺🇸
Hematology Oncology of the North Shore, Skokie, Illinois, United States
🇺🇸
Holy Cross Hospital, Ft. Lauderdale, Florida, United States

and more 17 locations

A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease

Phase 2

Withdrawn

Conditions: Chronic Graft-Versus-Host Disease

Interventions: Drug: LBH589
Drug: Methylprednisolone

First Posted Date: 2009-12-09

Last Posted Date: 2013-02-13

Lead Sponsor: SCRI Development Innovations, LLC

Registration Number: NCT01028313

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pazopanib
Drug: Erlotinib

First Posted Date: 2009-12-08

Last Posted Date: 2016-01-29

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 202

Registration Number: NCT01027598

Locations: 🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
South Carolina Oncology Associates, PA, Columbia, South Carolina, United States
🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

and more 5 locations

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Everolimus

First Posted Date: 2009-11-17

Last Posted Date: 2014-03-26

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 70

Registration Number: NCT01014351

Locations: 🇺🇸
Hematology Oncology Clinic, LLP, Baton Rouge, Louisiana, United States
🇺🇸
Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States
🇺🇸
Oncology Hematology of SW Indiana, Evansville, Indiana, United States

and more 9 locations

Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Phase 2

Terminated

Conditions: Intracranial Meningioma

Interventions: Drug: Everolimus
Drug: Bevacizumab

First Posted Date: 2009-09-04

Last Posted Date: 2021-11-10

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 18

Registration Number: NCT00972335

Locations: 🇺🇸
Nebraska Methodist Cancer Center, Omaha, Nebraska, United States
🇺🇸
Peninsula Cancer Institute, Newport News, Virginia, United States
🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States

and more 4 locations

SCRI Tissue Testing Registry

Terminated

Conditions: Melanoma
Myelodysplastic Syndrome
Multiple Myeloma
Lymphoma

Interventions: Other: Tissue Registry Study

First Posted Date: 2009-08-26

Last Posted Date: 2013-08-28

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 20

Registration Number: NCT00965861

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC

Phase 2

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Bevacizumab

First Posted Date: 2009-08-17

Last Posted Date: 2021-12-06

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 4

Registration Number: NCT00960297

Locations: 🇺🇸
Holy Cross Hospital, Fort Lauderdale, Florida, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸
Providence Medical Group, Terre Haute, Indiana, United States

and more 3 locations

Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Placebo
Drug: Everolimus
Drug: Bevacizumab
Drug: Paclitaxel

First Posted Date: 2009-06-08

Last Posted Date: 2014-12-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 113

Registration Number: NCT00915603

Locations: 🇺🇸
Wilshire Oncology Medical Group, LaVerne, California, United States
🇺🇸
Mercy Hospital, Portland, Maine, United States
🇺🇸
Aventura Medical Center, Aventura, Florida, United States

and more 12 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy